Stockscreener 앱 받기
0.2488
3.49%
0.0084
전일 마감가:
$0.2404
열려 있는:
$0.231
하루 거래량:
1.26M
Relative Volume:
1.09
시가총액:
$18.03M
수익:
-
순이익/손실:
$-30.01M
주가수익비율:
-0.2039
EPS:
-1.22
순현금흐름:
$-23.94M
1주 성능:
-12.64%
1개월 성능:
-22.61%
6개월 성능:
-72.96%
1년 성능:
-82.23%
1일 변동 폭
$0.2303
$0.2552
1주일 범위
$0.2303
$0.3164
52주 변동 폭
$0.217
$1.93
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.2488 | 18.03M | 0 | -30.01M | -23.94M | -1.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases - Business Wire
Annovis Bio 8-K Filing Reveals Investor Update and Presentation Details - Defense World
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times
INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan
Hyderabad's Suven to acquire controlling stake in Princeton based NJ Bio, Inc - Deccan Herald
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Attendee List for BevNET Live Winter 2024 - BevNET.com
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - GlobeNewswire
Annovis to Host Year-End Investor Webcast on December 11, 2024 - Quantisnow
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - The Manila Times
GRI Bio Showcases GRI-0621’s Potential to Reduce - GlobeNewswire
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
10 Biggest Biotechnology Companies - Investopedia
TāStation®'s analytical power used to resolve a central question about sweet taste perception - EurekAlert
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Gritstone bio : Bankruptcy Form 8 K - Marketscreener.com
US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results - Yahoo Finance
bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
SEC Form SC 13G filed by Bio-Rad Laboratories Inc. - Quantisnow
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - BioSpace
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - GlobeNewswire
NJ Bio, Inc. Wins Best CRO Award at 15th Annual World ADC Conference - Joplin Globe
Kronos Bio : Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives Form 8 K - Marketscreener.com
FMR LLC Bolsters Stake in Nuvation Bio Inc - GuruFocus.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - Quantisnow
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - GlobeNewswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
BioRestorative Therapies Enters at-the-Market Offering Agreement with Rodman & Renshaw LLC - Defense World
National Fuel Gas Updates Investor Presentation in Current ReportNational Fuel Gas Company (NYSE: NFG) has made notable updates to its Investor Presentation as detailed in a recent 8-K filing with the Securities and Exchange Commission on November - Defense World
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES - The Malaysian Reserve
Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy
Telesis Bio: Q3 Earnings Snapshot - New Haven Register
TELA Bio Inc (TELA) Quarterly 10-Q Report - Quartzy
Mustang Bio Inc (MBIO) Quarterly 10-Q Report - Quartzy
Pharma Pulse 11/8/24: Dusting Off One’s Cost Center Hat, Iron Supplements Benefit Children with HIV & more - Pharmaceutical Executive
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations - Yahoo Finance
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):